Inhibitors za Menin: Uburyo bushya bwo kuvura kanseri y'amaraso ya Myeloid Leukemia
Leukemia ya myeloid ikabije (AML) ni kanseri y’amaraso igoye kandi itandukanye irangwa no kwiyongera kw’uturemangingo tw’amaraso dukomoka kuri myeloid. Nubwo hari intambwe imaze guterwa mu kuvura, gukira AML biracyari ingorabahizi, cyane cyane ku barwayi bafite ibibazo byihariye bya genetiki. Ubushakashatsi buherutse kugaragazwa mu kinyamakuru Amaraso bashimangira akamaro k'ubuvuzi k'imiti igabanya ubukana bwa Menin, bagaragaza ubushobozi bwabo bwo guhindura uburyo bwo kuvura AML.
Uruhare rwa Epigenetics muri AML
Guhindura imiterere ya epigenetike, nka methylation ya ADN na histone modification, ni impinduka zishobora guhinduka zigenga igaragara rya gene zidahinduye urukurikirane rwa ADN. Izi mpinduka zigira uruhare runini mu iterambere rya AML. Kwibanda kuri izi nzira za epigenetike zishobora guhinduka bitanga uburyo bushya bwo kuvura.
Histones, poroteyine z'ingenzi mu ipaki ya ADN, zihinduka nyuma yo guhindura nk'acetylation na methylation, bigira ingaruka ku ihindurwa ry'uturemangingo. Menin, poroteyine ikoreshwa mu gupima imiterere y'uturemangingo ishingiye kuri gene ya MEN1, ni ingenzi cyane mu kugenzura epigenetike. Ikorana na histone methyltransferase KMT2A n'abandi bafatanyabikorwa kugira ngo igenzure igaragara ry'uturemangingo. Muri AML, Menin yorohereza gahunda zo guhindura oncogenic, cyane cyane binyuze mu kongera imiterere ya HOXA na MEIS1, ari na zo zitera ingenzi muri KMT2A-rearranged na NPM1-mutated AML.
Inhibitors za Menin: Iterambere mu kuvura AML
Ibyuma bigabanya ubukana bwa Menin ni molekile ntoya zigenewe kubangamira imikoranire hagati ya Menin na KMT2A, bityo zigahagarika inzira zo kwandukura kanseri. Izi nganda zagaragaje imikorere itangaje mu bushakashatsi bwakozwe mbere y’uko abaganga bavura ndetse n’ubwa muganga, cyane cyane kuri KMT2A-rearranged na NPM1-mutated AML, byose hamwe bikaba bigize itsinda rinini ry’abantu barwaye AML.
Umuti wa mbere wa Menin inhibitor, revumenib (SNDX-5613), wemejwe gukoreshwa mu buvuzi, hamwe n'indi myinshi, irimo ziftomenib (KO-539) na bleximenib, irimo kugeragezwa mu buvuzi. Igerageza rya AUGMENT-101 ryagaragaje ko revumenib yageze ku gipimo rusange cyo gusubiza (ORR) cya 53% mu gihe cy’indwara yo gusubira inyuma cyangwa idashobora kugaragara (R/R) AML, hamwe n’ingaruka mbi zishobora gukemuka nka QTc prolongation and differentiation syndrome. Mu buryo nk’ubwo, ibisubizo bya mbere byavuye mu igerageza rya KOMET-001 na KOMET-008 ryasuzumaga ziftomenib byagaragaje igipimo cyiza cyo kugabanya ububabare n’umutekano.
Uburyo bwo kuvura buvanze burimo gusuzumwa kugira ngo bwongere imikorere y’imiti igabanya ubukana bwa Menin. Ubushakashatsi buvanze revumenib n’imiti igabanya ubukana nka azacitidine na venetoclax bwagaragaje ko igipimo cy’ubutabazi kigera ku kigero cya 100% ku barwayi ba AML bameze neza n’abatameze neza, nubwo hakenewe ubundi bushakashatsi ku matsinda manini y’abantu.
Amabwiriza y'Umutekano n'ejo hazaza
Indwara zo mu bwoko bwa Menin muri rusange zigaragaza umutekano mwiza, ingaruka nyinshi zikaba zishobora gukemuka kandi zigakira. Ingaruka mbi zikunze kubaho zirimo ibimenyetso by'igifu, cytopenia, na differentiation syndrome. Imiterere y'ubuvuzi bugezweho itangwa na FDA yo muri Amerika kuri revumenib na ziftomenib igaragaza akamaro k'indwara zo mu bwoko bwa Menin mu gukemura ibibazo bitaragerwaho mu kuvura AML.
Amakuru meza ku buvuzi ku birebana n’imiti igabanya ubukana bwa Menin agaragaza intambwe ihinduka mu kuvura AML, atanga icyizere ku barwayi bafite ubwoko bw’uturemangingo tw’uturemangingo twagaragaye ko dufite ibibazo. Uko ubushakashatsi bukomeza, ubu buryo bwo kuvura bugiye kuvugurura uburyo bwo kwita kuri AML.
Ikigo Mpuzamahanga cy’Ubuvuzi cya BIOOCUS gikomeje kwiyemeza gukoresha uburyo bugezweho bwo kuvura indwara nka Menin inhibitors kugira ngo gitange ubuvuzi bushya kandi bufite akamaro ku barwayi ku isi yose.